GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Blood, American Society of Hematology, Vol. 109, No. 6 ( 2007-03-15), p. 2649-2656
    Abstract: CD4+CD25+ regulatory T cells (Tregs) suppress immune responses to alloantigens. The in vivo circulation and tissue localization of Tregs during an adaptive immune response remain unclear. We noninvasively tracked luciferase-expressing Tregs over time in an allogeneic bone marrow transplant model and demonstrated colocalization with effector T cells and initial expansion in secondary lymphoid organs before migration into inflamed tissues. Inflammation induced by irradiation and the allogeneic setting provided crucial stimuli for early Treg expansion and migration, leading to parallel reduction of effector T-cell proliferation in lymphoid organs and peripheral tissues. Treg transplants conferred long-term protection from systemic inflammatory challenge consistent with Treg in vivo survival. Suppression occurred during multiple phases of inflammation, but is optimal in the initial phase, providing protection from graft-versus-host disease while maintaining the graft-versus-tumor effect even at physiologic doses of Tregs due to their in vivo expansion, hence overcoming a major barrier to potential clinical applications of Tregs given their rarity.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2007
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Transplantation, Ovid Technologies (Wolters Kluwer Health), Vol. 80, No. 1 ( 2005-07-15), p. 134-139
    Type of Medium: Online Resource
    ISSN: 0041-1337
    RVK:
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2005
    detail.hit.zdb_id: 2035395-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Biology of Blood and Marrow Transplantation, Elsevier BV, Vol. 12, No. 7 ( 2006-07), p. 703-711
    Type of Medium: Online Resource
    ISSN: 1083-8791
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2006
    detail.hit.zdb_id: 3056525-X
    detail.hit.zdb_id: 2057605-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 2006
    In:  Current Opinion in Organ Transplantation Vol. 11, No. 1 ( 2006-02), p. 54-61
    In: Current Opinion in Organ Transplantation, Ovid Technologies (Wolters Kluwer Health), Vol. 11, No. 1 ( 2006-02), p. 54-61
    Type of Medium: Online Resource
    ISSN: 1087-2418
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2006
    detail.hit.zdb_id: 2026382-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 61-61
    Abstract: Abstract 61 In vivo models of complex immune processes like stem cell engraftment, host-pathogen interactions or anti-tumor responses face the challenge to either provide dynamic information in low resolution (e.g. in vivo bioluminescence Imaging, BLI) or provide high resolution information with a limited field of view (e.g. multi-photon laser scanning microscopy/confocal microscopy). To overcome these limitations we applied a novel selective plane illumination microscopy (SPIM) technique (also termed ultramicroscopy), which enabled us to visualize structural and cellular changes in intact organs in high resolution. Here we investigated dynamic shifts at sites of graft-versus-host disease (GVHD) initiation in mice after allogenic hematopoietic cell transplantation (allo-HCT). For in vivo and ex vivo imaging we transplanted 1,2×106 luciferase+ DsRed+ transgenic C57Bl/6 T cells (H-2b, Thy1.1+) plus 5×106 bone marrow (BM) cells (H-2b, Thy1.2+) into myeloablative conditioned allogeneic Balb/c recipients (H-2d, Thy1.2+, 8 Gy) to induce aGVHD. Utilizing BLI we followed the development of GVHD in vivo. At the transition from GVHD initiation phase to effector phase (day+3 and day+4) we prepared the small bowel and Peyer‘s Patches (PPs) of allo-HCT recipients for whole organ microscopy and compared these to organs of untreated mice. Staining for T cell populations (CD4) and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) allowed us to visualize MAdCAM-1 expression in relation to T cell areas in whole PPs and surrounding intestinal mucosa ( 〉 8mm3) in a high throughput format by creating approx. 1000 optical sections using multiple lasers and a sensitive CCD camera within 10 minutes. Adding another color channel revealed structural details through measurement of intrinsic autofluorescence. The individual color stacks were overlaid via computational image processing for three dimensional tissue reconstruction, volume measurements and quantification of protein expression. Ultramicroscopy exposed microanatomical structures like intestinal villi, crypts and PPs with its subepithelial dome regions and follicles by giving detailed information about MAdCAM-1 expressing blood vessels and T cell areas. The 3D reconstruction of small intestines in non-conditioned mice revealed that the MAdCAM-1 expression averaged at 1-2% of the entire PP and was predominantly restricted to the high endothelial venules (HEV). During the transition from the initiation to the effector phase of acute GVHD (day3-4) the overall MAdCAM-1 expression in PPs increased by 50fold. At this point MAdCAM-1 expression was also found in parafollicular and subepithelial cell populations, which still need to be characterized further concerning their lineage differentiation. MAdCAM-1 is well known as a vascular addressin molecule. Because of its importance in homing of α4β7+ T and B cell into the gastrointestinal tract we investigated the dynamic expression of MAdCAM-1 during acute GVHD within intact PPs. It is well established that MAdCAM-1 is an important regulator in the homing of α4β7+ T cell to PPs via HEVs. Additionally our data lead to the hypothesis that MAdCAM-1 might contribute to retain proliferating α4β7+ T cells during the initiation of an adaptive immune response and might support a synchronized exit of alloreactive T cells in the aGVHD effector phase. Conventional histological sections are labor intensive, time consuming and often restricted to a very limited region of interest and therefore, can result in missing rare events and under- or overestimation of biological processes. Ultramicroscopy helped us to overcome these limitations and enabled us to visualize immunological processes with subcellular resolution in whole organs. CB and MF, GSH and AB contributed equally to this work. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Wiley ; 2009
    In:  International Journal of Cancer Vol. 124, No. 1 ( 2009-01-01), p. 239-244
    In: International Journal of Cancer, Wiley, Vol. 124, No. 1 ( 2009-01-01), p. 239-244
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 64-64
    Abstract: Regulatory T cells (Treg), defined phenotypically by CD4+CD25+ expression, reduce the incidence and severity of acute graft-versus-host disease (GvHD) in murine models of major-MHC mismatched hematopoietic cell transplantation (HCT), presumably by dampening the proliferation and activation of mature effector T cells. It is unclear whether the effect of Treg on effector T cells is a selective or nonselective process or if Treg regulate the process of intrathymic and peripheral T cell maturation and selection following HCT, particularly given the intrinsic link of GvHD and immune reconstitution. The current study assessed the impact of Treg on the quantitative and functional lymphoid reconstitution in a murine model of major-MHC mismatched HCT. Treg (5x105) from the spleen and lymph nodes of FVB/N (H2q) mice were co-transplanted into lethally irradiated Balb/c (H2d) host along with wild-type FVB/N T-cell depleted bone marrow (TCD-BM) cells (5x106) and splenocytes (1.25x106) (Tcon), the latter to induce GvHD. Chimerism studies were performed on day 14 and 40 post-transplantation to measure the level of donor immune reconstitution. At both time points, total lymphoid reconstitution was delayed in the GvHD control group and enhanced in the recipients transplanted with Treg (p-values=0.0005 on day 14, & lt;0.0001 on day 40). T cell reconstitution, particularly CD4+ cells, was enhanced in the Treg group at both time points and reached statistical significance on day 40 (p-value=0.003). The number of donor natural killer cells was particularly enhanced on day 14 in the Treg recipients (p-value=0.0003). B-cell reconstitution, as measured by percentage of CD19+ cells, was minimal for all groups at day 14, but was enhanced at day 40 in recipient animals that received Treg (p-value=0.006). The T cell repertoire assessed by V-beta TCR screening with FACS analysis showed a polyclonal distribution. To determine if the improved and diverse lymphoid reconstitution is associated with increased immune function, mice were challenged with murine CMV (5x10e5 pfu/mouse) intraperitoneally at day 14 post-transplantation. Two weeks after infection, 66% of animals which received Treg in addition to Tcon, and 11% of animals which received Tcon alone were alive (p-value=0.05). Uninfected mice in the respective groups served as controls to separate the effect of CMV infection and GvHD on survival. Compared to infected animals, no deaths were observed in the respective uninfected groups at this time point (Tcon alone, p-value=0.0004; Treg+Tcon, p-value=0.21). In both infected and control uninfected animals, Treg treated animals had no evidence of significant clinical GvHD while animals that received Tcon alone had severe GvHD. These findings indicate that Treg enhance both the quantitative and functional recovery of the lymphoid cell populations while providing protection against GvHD.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Society of Hematology ; 2008
    In:  Blood Vol. 112, No. 11 ( 2008-11-16), p. 3520-3520
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 3520-3520
    Abstract: Allogeneic hematopoietic cell transplantation (HCT) is an effective treatment for a variety of hematologic malignancies. However, overall success of HCT is limited due to the immunologic recognition and destruction of host tissues resulting in graft-versus-host-disease (GvHD). In GvHD, donor derived immune cells recognize and destroy recipient epithelial tissues; predominantly liver, gastrointestinal (GI) mucosa, and skin. It has been reported that GI toxicity and crypt loss is a strong predictor of GvHD morbidity and mortality. Therefore, GI protective strategies may diminish GvHD severity. R-spondin1 (Rspo1) is an epithelial mitogen that stimulates mucosal growth in both small and large intestines. Therapeutic administration of Rspo1 has been shown to reduce the loss of body weight, diarrhea and rectal bleeding in experimental mouse colitis models. Histological evaluation revealed that Rspo1 improved mucosal integrity by stimulating crypt cell growth and mucosal regeneration in colitis-induced mice. Because the symptoms and pathogenesis of GI-GvHD are similar to colitis models, we chose to examine the impact of Rspo1 on mice with GvHD. Conventional CD4+/CD8+ T cells (Tconv) isolated from FVB (H-2q) animals were transplanted along with T cell-depleted bone marrow (TCD-BM) into lethally irradiated BALB/c (H-2d) mice. Mice received either 100μg Rspo1 protein in 100μL PBS or 100μL PBS alone IV from day 1 to day 6 post-transplantation. Surprisingly, mice receiving Rspo1 had significantly increased rates of mortality. Mice receiving Rspo1 experienced 100% mortality by day 6 post-HCT. In contrast, mice receiving only PBS demonstrated 0% mortality at 20 days post-HCT. Mortality was not a result of Rspo1 toxicity, as no morbidity or mortality was observed in the absence of allogenic Tconv in mice transplanted with either syngenic HCT or allogeneic TCD-BM alone. In order to assess whether the higher mortality experienced by Rspo1 treated mice was due to an explosive proliferation of Tconv, the transplant experiment was repeated with donor Tconv isolated from luciferase transgenic (luc+) H-2q mice. Groups receiving Rspo1 versus PBS did not show significantly different bioluminescence imaging signal intensity, suggesting that rapid proliferation of donor Tconv was not the basis for the observed differences in mortality. The overall mouse mortality in this experiment was consistent with the previous experiment. In an attempt to uncover the mechanism, we found no differences in the Perforin-Granzyme B or Fas/Fas ligand expression between control and treatment groups. Cytokine milieu (IFNγ, TNFα, IL-17, and IL-2) assessment in transplanted mice did not show significant differences in cytokine profiles of control versus Rspo1 treatment. Mouse autopsy demonstrated that transplanted mice receiving Rspo1 had marked crypt hyperplasia, apoptotic cells, and increased mitoses when compared PBS recipients. All other organ systems were considered normal in both groups by a veterinary pathologist. Blood cultures of both groups were negative for bacteria. CBC, liver enzymes, and electrolyte panels were normal in both groups. In order to assess lethal irradiation as a contributing factor to the increased mortality of Rspo1 treated mice, we repeated the above transplant experiment including non-irradiated immunodeficient Rag2−/−, γ-chain−/− H-2d recipients in addition to the lethally irradiated H-2 d recipients. Our mortality findings in the lethally irradiated group were consistent with the above mentioned transplant experiments showing rapid mortality rates in recipient mice receiving Rspo1. However, non-irradiated Rag2−/− γ-chain−/− mice that received Rspo1 had almost identical mortality rates to those receiving PBS; all mice surviving over 20 days post HCT. This finding underlines the critical importance of lethal irradiation as a contributing factor in Rspo1 treatment mortality. These findings suggest that the beneficial effects of Rspo1 in the colitis model may not be reproducible in GvHD. Furthermore, our studies indicate that the lethal effects of Rspo1 may be due to a myriad of factors including allogenic mismatch and lethal irradiation.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 3162-3162
    Abstract: CD4+CD25+FOXP3+ natural occurring T regulatory (Treg) cells possess great therapeutic potential as adoptive cellular therapy for controlling autoimmune diseases and acute GVHD. However, the clinical application of human Treg is limited by the difficulty of obtaining sufficient numbers of CD4+CD25+FOXP3+ cells. This study explored a strategy to expand human Treg in high purity and high numbers. By comparing expression of cell surface molecules on sorted CD4+CD25High versus CD4+CD25- cells using mAb microarray, we identified CD127 was highly expressed in CD4+CD25- and CD4+CD25Low cells in human PBMC. This was confirmed by two recent reports. Incorporating this new discovery, CD4+CD25+ cells were isolated by CD25+ selection from PBMC of healthy blood donors. The selected CD25+ cells were sorted into CD4+CD25HighCD127Low and CD4+CD25LowCD127High cells. FOXP3 were positive in 94% of CD4+CD25HighCD127Low cells, and 5% in CD4+CD25LowCD127High cells. The sorted cells were expanded with and without rapamycin at concentrations between 1–100ng/ml in X-vivo medium containing IL-2 and anti-CD3/CD28 beads. The anti-CD3/CD28 beads were removed at day 7 and cells were cultured for a total of 21 days. In the absence of rapamycin, CD4+CD25+CD127Low cells expanded 28 folds, yet only 60% were FOXP3 positive at day 7. At day 14 and 21, only 30% and 20% of the expanded cells were positive for FOXP3, although cells expanded 156 and 1560 folds respectively. In the presence of rapamycin between 1ng/ml and 20ng/ml, sorted CD4+CD25+CD127Low cells remain FOXP3+ in 96%, 60% and 56% at days 7, 14 and 21. However, the number of cells increased only 19, 36, and 21 folds at days 7, 14 and 21 respectively. To overcome the insufficient expansion of CD4+CD25+CD127Low cells in the presence of rapamycin, anti-CD3 mAb (OKT3) or anti-CD3/CD28 beads was added to the media at day 7 after the initial beads were removed and cultured until day 21. At day 14, 66% of the cells were FOXP3 positive with rapamycin and anti-CD3 and 80% for cells with rapamycin and ani-CD3/CD28 beads. The numbers of cells were expanded: 13 folds with rapamycin and anti-CD3, and 238 folds with rapamycin and ani-CD3/CD28 beads. At day 21, the numbers of cells were expanded: 34 folds with rapamycin and anti-CD3, and 2856 folds with rapamycin and ani-CD3/CD28 beads. The suppressive function of expanded cells on allogeneic proliferation of conventional CD4 T cells in the mixed lymphocytes reaction (MLR) was positively correlated with the percentage of FOXP3 positive cells added to the culture. In contrast, the sorted CD4+CD25LowCD127High cells expanded in the same condition as controls had much lower percentages of FOXP3+ cells with or without rapamycin and in the presence or absence of coupled anti-CD3/CD28 beads although the numbers of cells were expanded much higher. In summary, sorted human CD4+CD25HighCD127Low cells were 94% FOXP3+. Without rapamycin, the FOXP3 negative cells expanded much faster and dominated the expanded cell population at day 14 and 21. In the presence of rapamycin, CD4+CD25HighCD127LowFOXP3+ cells were preferentially expanded with IL-2 and anti-CD3/CD28 beads. Continued stimulation from anti-CD3/CD28 beads enhanced the expansion of CD4+CD25HighCD127LowFOXP3+ cells. The expanded cells are functionally suppressive on allogeneic proliferation of conventional CD4+ T cells.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 5466-5466
    Abstract: The efficacy of high dose therapy (HDT) and autologous hematopoietic cell transplantation (AHCT) for patients with diffuse large cell non-Hodgkin’s lymphoma (NHL) who never achieve a first complete remission (CR) with conventional chemotherapy have been addressed by few published studies. We retrospectively analyzed outcomes for 43 consecutive patients with chemotherapy-sensitive primary refractory diffuse large cell NHL treated with HDT and AHCT at our center between November 1988 and January 2002. The median age at transplant was 43 years (range: 18 – 64). At diagnosis 26 patients (60%) had stage IV disease, 28 patients (65%) had extranodal involvement, and bulky disease was present in 17 patients (40%). The age-adjusted NHL international prognostic index (IPI) score was low in 4 patients (9%), low-intermediate in 18 patients (42%), high or high-intermediate in 12 patients (28%), and not available in 9 patients (21%). All patients failed to achieve a first CR following CHOP (n = 31, 72%), R-CHOP (n = 6, 14%), and other anthracycline-containing regimens (n = 6, 14%). Fourteen patients (33%) did not receive additional conventional chemotherapy before proceeding to HDT and AHCT. The remaining 29 patients (67%) received in addition between 1 – 6 cycles of salvage chemotherapy. None of the 43 patients had achieved a CR at any time point before HDT and AHCT and all patients had measurable disease at the start of the HDT regimen. The median interval from diagnosis to HDT was 8.9 months (range: 2.4 – 15.5). The HDT regimen consisted of total body irradiation, etoposide, and cyclophosphamide in 15 patients (35%); BCNU, etoposide, and cyclophosphamide in 26 patients (60%); and CCNU, etoposide, and cyclophosphamide in 2 patients (5%). All but three patients (7%) were rescued with peripheral blood stem cells mobilized with cyclophosphamide 4 gm/m2 plus G-CSF and purged with monoclonal antibodies and complement. With a median follow-up of 5.8 years (range: 0.2 – 15.8) among surviving patients, the 5-year Kaplan-Meier estimates for overall survival was 67.4% (95% CI: 52.4 – 82.4), freedom from progression was 60.1% (95% CI: 43.7 – 76.6), and event-free survival was 55.8% (95% CI: 39.2 – 72.4). Two patients with relapse post-AHCT proceeded to non-myeloablative allogeneic HCT and were censored at the time of second transplant. By univariate analyses the following characteristics were not prognostically significant for overall survival: disease stage at diagnosis (I–II versus III–IV), prior radiotherapy, age-adjusted IPI score (low versus high) in evaluable patients, and the HDT regimen (TBI versus non-TBI). These results demonstrate that HDT and AHCT is effective treatment for chemotherapy-sensitive primary refractory diffuse large cell NHL. Figure Figure
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...